Trials / Recruiting
RecruitingNCT07490041
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric Rheumatic Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine · Academic / Other
- Sex
- All
- Age
- 5 Years
- Healthy volunteers
- Not accepted
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.
Conditions
- Rheumatic Diseases
- Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
- Systemic Lupus Erythematosus (SLE)
- Connective Tissue Disease-associated Interstitial Lung Disease
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | KN5601 | Multiple doses of anti-CD19/BCMA CAR-NK cells (KN5601) will be administered using dose-escalation strategy. |
Timeline
- Start date
- 2026-03-19
- Primary completion
- 2026-12-19
- Completion
- 2027-12-19
- First posted
- 2026-03-24
- Last updated
- 2026-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07490041. Inclusion in this directory is not an endorsement.